Moderna Shares Fall After Analyst Day Guidance and Higher Cost Outlook
Moderna guided for 15–25% revenue growth in 2026 and said cash costs will rise to approximately $4 billion in 2027, remaining elevated through 2030.
Moderna guided for 15–25% revenue growth in 2026 and said cash costs will rise to approximately $4 billion in 2027, remaining elevated through 2030.
Moderna lifted its 2026 revenue growth forecast to 15–25% after strong international COVID vaccine sales helped it return to profit in Q3.
TD Cowen calls Phase 3 intismeran + Keytruda results “compelling” and in the exceptional range. Wells Fargo says RFS exceeded expectations.
Citi says Moderna’s rally after the INTerpath-001 melanoma win pushed its market value near Regeneron’s despite weaker near-term earnings.
Moderna intends to sell $2B of zero-coupon notes due 2032, plus a $300M option, after a melanoma vaccine rally. Shares slipped on dilution risk.
Wolfe Research upgrades Moderna to Peer Perform following Phase 3 intismeran success and a potential $9.2 billion peak sales outlook.